

FOR IMMEDIATE RELEASE

DTI-Tech and MTTlab announce strategic collaboration in drug target identification and preclinical oncology research

The collaboration connects target identification and rapid resistance modelling with functional in vitro and in vivo validation.

TRIESTE, Italy and BELLINZONA, Switzerland — October 29, 2026

MTTlab and DTI-Tech today announced a strategic collaboration combining complementary expertise in drug target identification, mechanism-of-action investigation, drug resistance research and preclinical validation. The collaboration will support biotechnology and pharmaceutical companies seeking a coordinated approach to investigate therapeutic mechanisms, anticipate resistance and define translational validation strategies in oncology.

DTI-Tech contributes its proprietary drug target identification method and the IFDREAM platform, a next-generation platform for drug target identification and rapid resistance modelling. MTTlab contributes functional in vitro testing and in vivo efficacy models, enabling discoveries generated through DTI-Tech technologies to be assessed in tailored preclinical programmes.

Integrated research capabilities

A central element of the collaboration is the combined investigation of drug targets and pathway modulation in rapidly generated drug-resistant cellular models. Depending on the research question, these capabilities can be connected with MTTlab assays and disease-relevant models to support target validation, resistance studies, combination strategies and translational proof of concept.

- Drug target identification through the DTI-Tech method
- Mechanism-of-action investigation
- Combined study of drug target identification and pathway modulation in rapidly generated drug-resistant models using the IFDREAM platform
- Generation and characterization of drug-resistant cell models
- Identification of resistance-associated pathways
- Functional validation and combination studies
- In vivo translational proof of concept

Projects will be scoped according to each client's research question, development stage and validation needs. The companies may support focused studies or broader programmes extending from target identification and resistance modelling to functional assessment and in vivo validation.

Leadership perspectives

"We are pleased to collaborate with MTTlab, whose expertise in functional pharmacology strongly complements DTI-Tech's capabilities in drug target identification and resistance modelling. By combining our respective approaches, we aim to support more informed and efficient decision-making in preclinical drug development, particularly in challenging oncology settings."

Eugenio Gaudio, COO, DTI-Tech

“This collaboration expands MTTlab’s ability to offer integrated preclinical research programmes, connecting target identification and resistance studies with functional in vitro and in vivo validation. Working together allows us to provide clients with a coordinated approach tailored to different stages of the preclinical research process.”

Cristina Degrassi, CEO, MTTlab

MTTlab and DTI-Tech will jointly define the scope, responsibilities and activities for each research programme. Financial and contractual terms of the collaboration have not been disclosed.

About MTTlab

MTTlab is an independent preclinical contract research organization based in Trieste, Italy. Founded in 2015, the company supports biotechnology companies, pharmaceutical developers and academic research groups through tailored early-stage and proof-of-concept studies. Its capabilities include functional in vitro testing and in vivo pharmacology, with expertise in oncology, inflammation, pharmacokinetics, biodistribution and non-GLP toxicology. MTTlab combines direct scientific oversight, flexible study design and clear project communication to help clients make timely development decisions.

About DTI-Tech

DTI-Tech is a Swiss biotechnology company focused on drug target identification and the rapid generation of drug-resistant disease models. The company develops integrated technologies designed to help pharmaceutical and biotechnology companies identify therapeutic targets, investigate mechanisms of action and anticipate resistance mechanisms earlier in preclinical development. Its technologies include the DTI-Tech method and IFDREAM, a next-generation platform for drug target identification and rapid resistance modelling.

Media contacts

Cristina Degrassi

CEO, MTTlab
degrassi@mttlab.eu
www.mttlabor.eu

Eugenio Gaudio

COO, DTI-Tech
gaudio@dtitech.ch
www.dtittech.ch